Related Experiment Video

Updated: Jun 18, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a

Christopher F Bell1, Tasneem Lokhandwala2, Daniel C Gibbons3

  • 1GSK, Research Triangle Park, Durham, North Carolina.

Clinical Therapeutics
|February 5, 2025
PubMed

Insights

Sotrovimab significantly reduced severe outcomes in high-risk COVID-19 patients during Delta and Omicron variants. This monoclonal antibody treatment lowered hospitalization and mortality risks, particularly in older adults.

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Coronavirus disease 2019 (COVID-19) poses significant public health challenges.
  • Monoclonal antibodies have been developed as therapeutic options for COVID-19.
  • Effectiveness of treatments can vary with emerging viral variants.

Purpose of the Study:

  • To evaluate the real-world effectiveness of sotrovimab in preventing severe clinical outcomes in COVID-19 patients.
  • To compare sotrovimab treatment against no treatment during the Delta and early Omicron variant periods.

Main Methods:

  • Retrospective analysis of US administrative claims data (May 2021 - April 2022).
  • Inclusion of cohorts for early treatment (sotrovimab, other monoclonal antibodies, antivirals), prophylaxis, and untreated patients.
  • Matched cohort analysis comparing sotrovimab-treated and untreated patients for severe outcomes (hospitalization, mortality, ventilatory support/ECMO, length of stay) within 29 days post-treatment.

Main Results:

  • Sotrovimab treatment significantly reduced hospitalization (4.0% vs 4.7%), hospitalization and/or mortality (4.0% vs 5.2%), and need for ventilatory support/ECMO (3.6% vs 6.5%) compared to no treatment.
  • Benefits were most pronounced in patients aged 55 years and older, especially those ≥65 years (OR 0.56).
  • Effectiveness was observed across Delta, Omicron BA.1, and BA.2 variant periods.

Conclusions:

  • Sotrovimab is associated with a reduced risk of severe clinical outcomes in high-risk COVID-19 patients.
  • The benefit was evident during the Delta and early Omicron variant waves.
  • Findings support the use of sotrovimab for eligible high-risk individuals.
Abstract

Keywords:
COVID-19Omicron BA.1Omicron BA.2SARS-CoV-2monoclonal antibodysotrovimab

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-1908:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.8K

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...